-
Ramucirumab by Eli Lilly and Co for Gallbladder Cancer: Likelihood of Approval
18 Apr 2024 03:41 GMT
… been previously treated with sorafenib. Cyramza in combination … non-small cell lung cancer with activating epidermal … squamous non-small cell lung cancer, metastatic colorectal cancer, … gallbladder cancer, small-cell lung cancer and metastatic thymic carcinoma …
-
Everolimus by Novartis for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
18 Apr 2024 03:41 GMT
… of treatment with sunitinib or sorafenib, adults with renal angiomyolipoma and … , glioblastoma multiforme, non-small cell lung cancer, myeloblastic syndrome, metastatic colorectal cancer …
-
CDSCO Panel Approves Roche's Protocol Amendment Proposal For Anti-cancer Drug Atezolizumab, Lenvatinib, and Sorafenib Study
14 Apr 2024 16:10 GMT
… Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in … lenvatinib or sorafenib versus lenvatinib or sorafenib alone in … prevent non-small cell lung cancer (NSCLC) from coming … potent antiangiogenic properties.
Sorafenib is used to treat …
-
Emerging Insights into Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Immune Checkpoint Inhibitor and Tumor-Targeted Therapy
17 Apr 2024 07:31 GMT
… an EGFR-mutated lung cancer patient. Lung Cancer. 2016;95:35 … epidermal necrolysis associated with sorafenib and tosufloxacin in a … advanced non-small cell lung cancer and comorbid pulmonary tuberculosis … necrolysis in a lung cancer patient harboring an …
-
Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer
07 Feb 2024 12:27 GMT
… cancers to date, including lung cancer, bladder cancer, esophageal … response (MPR).
About Lung Cancer
Lung cancer is the leading cause … previously treated with sorafenib. This indication is … lung cancer; Checkmate 816-neoadjuvant non-small cell lung cancer, …
-
Merck and Moderna Initiate INTerpath-002, a Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Certain Types of Resected Non-Small Cell Lung Cancer
11 Dec 2023 11:56 GMT
… -small cell lung cancer.”
“Addressing lung cancer reflects the … rank=1.
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … previously treated with sorafenib. This indication is …
-
Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LYNPARZA® (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility
07 Dec 2023 12:21 GMT
… lung cancer.”
Merck has an extensive clinical development program in lung cancer … toxicity.
About lung cancer
Lung cancer is the … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … treated with sorafenib. This indication …
-
Merck Announces Findings from Phase 2 KeyVibe-002 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab in Previously Treated Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)
07 Dec 2023 11:36 GMT
… non-small cell lung cancer (NSCLC) with … docetaxel alone.
About lung cancer
Lung cancer is the leading cause … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … previously treated with sorafenib. This indication is …
-
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by 28% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)
20 Oct 2023 12:17 GMT
… in certain advanced lung cancers, these overall … were identified.
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer … previously treated with sorafenib.
This indication is …
-
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Provides Benefits for Patients with Resectable Non-Small Cell Lung Cancer Across PD-L1 Expression Levels with Three-Year Follow Up in CheckMate -816 Trial
17 Oct 2023 20:05 GMT
… stage tumor types, including lung cancer, bladder cancer, esophageal … distant metastases.
About Lung Cancer
Lung cancer is the leading … previously treated with sorafenib. This indication is … lung cancer; Checkmate 816–neoadjuvant non-small cell lung cancer, …